The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
29 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,683,463 in first-year total cost, median $198,578.
Most frequent study sections
- Special Emphasis Panel[ZCA1 RPRB-F (M1)]2
- Special Emphasis Panel[ZCA1 RPRB-M (M1)]2
- Special Emphasis Panel[ZCA1 RPRB-M (M2)]2
- Special Emphasis Panel[ZCA1 RPRB-M (M5)]2
- Special Emphasis Panel[ZCA1 RTRB-F (J2)]2
Most frequent institutions
- UNIVERSITY OF TX MD ANDERSON CAN CTR3
- INDIANA UNIVERSITY INDIANAPOLIS2
- UNIVERSITY OF MICHIGAN AT ANN ARBOR2
- BAYLOR COLLEGE OF MEDICINE1
- BRIGHAM AND WOMEN'S HOSPITAL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Sequence variation in mtDNA and extreme survival in glioblastoma1R21CA216227-01 | EGAN, KATHLEEN M.WILLIAMS, SION LLEWELYN | H. LEE MOFFITT CANCER CTR & RES INST, FL | $249,944 | ZCA1 |
| 2017 | (PQ 5) Roles of mitochondrial heterogeneity in cell survival and oncogenesis1R21CA216304-01 | NEWMEYER, DONALD DAVID | LA JOLLA INSTITUTE FOR IMMUNOLOGY, CA | $234,900 | ZCA1 |
| 2017 | Uncovering Gene Expression Differences between Benign and Premalignant Colorectal Polyps1R21CA208461-01A1 | VILAR SANCHEZ, EDUARDO | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $219,902 | ZCA1 |
| 2017 | (PQ1) Cellular senescence as an initiating event in malignant transformation1R21CA206013-01A1 | DAVID, GREGORY | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $203,400 | ZCA1 |
| 2017 | Investigating developmental Hox programs as determinants of sarcomagenesis1R21CA215968-01 | LAWLOR, ELIZABETH RWELLIK, DENEEN M | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $202,275 | ZCA1 |
| 2017 | (PQ#9): Altered mitochondrial transport and chemotherapy-induced peripheral neuropathy1R21CA215985-01 | CHANG, KAREN T | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $198,000 | ZCA1 |
| 2017 | Determining the Influence Genomic Instability During Embryogenesis has on Tumor Penetrance1R21CA219546-01 | PARANT, JOHN M | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $193,793 | ZCA1 |
| 2017 | (PQ7) A multi-fluorescent intravital microscopy approach to study osteosarcoma1R21CA208618-01A1 | INTINI, GIUSEPPE | HARVARD MEDICAL SCHOOL, MA | $191,221 | ZCA1 |
| 2017 | Telomere-related Genomic Instability in Early Colorectal Carcinogenesis1R21CA205434-01A1 | TANAKA, HIROMI | INDIANA UNIVERSITY INDIANAPOLIS, IN | $187,200 | ZCA1 |
| 2017 | PQ-10: Microbial metabolite, Urolithin A is a potent immunomodulator and chemosensitizing adjuvant in treating colon cancer.1R21CA216090-01 | JALA, VENKATAKRISHNA RAO | UNIVERSITY OF LOUISVILLE, KY | $167,475 | ZCA1 |
| 2017 | Impact of macrophage PCSK9 on breast cancer1R21CA216230-01 | FAN, DAPING | UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA, SC | $160,200 | ZCA1 |
| 2017 | (6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma1R21CA208736-01A1 | MURPH, MANDI M | UNIVERSITY OF GEORGIA, GA | $146,000 | ZCA1 |
| 2016 | (PQ10) Do microbiota alter the epigenetic landscape in human genome1R21CA208464-01 | STRONGIN, ALEX Y | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $254,475 | ZCA1 |
| 2016 | (PQ9) Dual Action RSK Inhibitor: Targeting Metastasis and Providing Cardioprotection1R21CA208631-01 | LANNIGAN, DEBORAH | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $251,120 | ZCA1 |
| 2016 | (1) Intestinal Organoid Models for APC LOH1R21CA208638-01 | GIARDINA, CHARLES A. | UNIVERSITY OF CONNECTICUT STORRS, CT | $232,195 | ZCA1 |
| 2016 | Novel Mouse Models to define Genetic Drivers of Aggressive Prostate Cancer1R21CA205627-01 | ELLIS, LEIGH | ROSWELL PARK CANCER INSTITUTE CORP, NY | $223,808 | ZCA1 |
| 2016 | (PQ4) Elucidating Determinants of Susceptibility to Tumorigenesis in the Skin1R21CA208298-01 | RAMSEY, MATTHEW ROBERT | BRIGHAM AND WOMEN'S HOSPITAL, MA | $217,016 | ZCA1 |
| 2016 | (PQ 6) Exploiting Frequent Alterations in the PRC2 Complex to Distinguish Benign Neurofibromas from Malignant Peripheral Nerve Sheath Tumors1R21CA208723-01 | BETTEGOWDA, CHETAN | JOHNS HOPKINS UNIVERSITY, MD | $212,824 | ZCA1 |
| 2016 | (PQ4) Mutations in the histone chaperone DAXX drive pancreatic neuroendocrine tumors not ductal adenocarcinomas1R21CA208463-01 | LOZANO, GUILLERMINA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZCA1 |
| 2016 | The Role of Mitochondrial Heterogeneity in Pyruvate Flux in Prostate Cancer Progression1R21CA205257-01 | MCGUIRE, SEAN E | BAYLOR COLLEGE OF MEDICINE, TX | $206,843 | ZCA1 |
| 2016 | Unlocking Tumor Immunophenotype in Responders versus Non-Responders in Metastatic Uveal Melanoma Patients Receiving Immune Checkpoint Blockade1R21CA208609-01 | PATEL, SAPNA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $203,580 | ZCA1 |
| 2016 | (PQ3) Modulation of Osteosarcoma Biology by Inflammation and Immunity Defined through a ComparativeApproach1R21CA208529-01 | MODIANO, JAIME F. | UNIVERSITY OF MINNESOTA, MN | $198,578 | ZCA1 |
| 2016 | (PQ9) Prevention of Bleomycin-induced Pulmonary Toxicity by Dichloroacetate (DCA)1R21CA208746-01 | KIM, JUNG-WHAN | UNIVERSITY OF TEXAS DALLAS, TX | $198,485 | ZCA1 |
| 2016 | Pax2 loss in fallopian tube lesions and strategies for restoration in serous cancer1R21CA208610-01 | BURDETTE, JOANNA E | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $196,475 | ZCA1 |
| 2016 | PQ3: Age-related immune deviation and cancer outcome1R21CA205430-01 | KUMMAR, SHIVAANIMAECKER, HOLDEN T. | STANFORD UNIVERSITY, CA | $171,825 | ZCA1 |
| 2016 | (10.) The Gut Microbiome and Responses to Neoadjuvant Chemoradiation in Rectal Cancer Patients1R21CA205636-01 | CHEN, GRACE Y. | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $168,563 | ZCA1 |
| 2016 | (PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy1R21CA205644-01 | BOYIADZIS, MICHAELWHITESIDE, THERESA L. | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $167,475 | ZCA1 |
| 2016 | "(PQ8) BONE MARROW-ON-A-CHIP":AN INVITRO 3D MODEL OF BREAST CANCER DORMANCY1R21CA208519-01 | GEORGE, STEVEN CARL | WASHINGTON UNIVERSITY, MO | $165,844 | ZCA1 |
| 2016 | (PQ9) Novel therapeutic approaches to chemotherapy-induced muscle.1R21CA205437-01 | WANING, DAVID L | INDIANA UNIVERSITY INDIANAPOLIS, IN | $51,247 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.